Eris has outpaced the Indian Pharmaceutical Market (IPM) growth with a CAGR of 33.9% in Chronic and 20.1% in Acute therapy segment.
Chronic category contributes to over 64.2% of our revenues as compared to 33.4% contribution to the IPM.
Eris is the fastest growing company in Chronic therapy amongst the top 25 companies.
We are the 2nd fastest growing company in Cardiovascular and Anti Diabetics therapeutic segments amongst the top 25 companies.
Source : IMS TSA FY 2016,Compounded annual growth rate between Fiscal 2012 and 2016
Source : IMS TSA (Compounded annual growth rate between Fiscal 2012 and 2016)
Our field force productivity (YPM – Yield per Man per Month) is industry leading and we are amongst most productive companies in the Industry.
Our product portfolio is primarily focused on therapeutic areas which require the intervention of super specialist and specialist doctors such as Diabetologists, Endocrinologists Cardiologists, and Gastroenterologists. We have a prescriber base of 49476 doctors for Fiscal 2016 as per IMS medical audit.
Super specialist and specialist doctor prescription contribution
Source IMS Medical Audit MAT September,2016
Eris has a portfolio of high growth prescription products. We derive majority of our prescriptions from molecules which are in growth phase of the product lifecycle.
|Lifecycle of Pharmaceutical Molecules||Eris Lifesciences||IPM|
Source: SMSRC, MAT October 2016.
|Doctor Specialty||Rank FY 2016|
Source IMS Medical Audit FY 2016, Prescription rank within Eris represented market